Activating mutations in PIK3CB confer resistance to PI3K inhibition and define a novel oncogenic role for p110β

Cancer Research

Volumn 76, Issue 5, 2016, Pages 1193-1203

  Nakanishi, Yoshito ^a,b   Walter, Kimberly ^a   Spoerke, Jill M ^a   O'Brien, Carol ^a   Huw, Ling Y ^a   Hampton, Garret M ^a   Lackner, Mark R ^a  

^a GENENTECH INC   (United States)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APITOLISIB; CRIZOTINIB; DOCETAXEL; ERLOTINIB; GDC 0349; IPATASERTIB; LAPATINIB; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PICTILISIB; PROTEIN KINASE B; PROTEIN P110; PROTEIN P110BETA; TASELISIB; UNCLASSIFIED DRUG; VORINOSTAT; PIK3CB PROTEIN, HUMAN; PTEN PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER RECURRENCE; CELL MEMBRANE; CELL VIABILITY; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; ENZYME INHIBITION; GENE ACTIVATION; GENE ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENE LOCATION; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; ONCOGENE; PIK3CB GENE; PRIORITY JOURNAL; PROTEIN DEPLETION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DEFICIENCY; DRUG RESISTANCE; FEMALE; GENETICS; MUTATION; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PTEN PHOSPHOHYDROLASE;

EID: 84961684139     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-2201     Document Type: Article

References (49)

1. Samuels Y, Wang ZH, Bardelli A, Silliman N., Ptak J, Szabo S, et al High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304:554.
2. Bourgon R, Lu S, Yan Y., Lackner MR, Wang W, Weigman V, et al High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing. Clin Cancer Res 2014; 20:2080-91.
3. Carpten JD, Faber AL, Horn C, Donoho G.P., Briggs SL, Robbins CM, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007; 448:439-44.
4. Rodon J, Dienstmann R, Serra V., Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 2013; 10:143-53.
5. Dienstmann R, Rodon J, Serra V., Tabernero J. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther 2014; 13:1021-31.
6. Motzer RJ, Escudier B, Oudard S., Hutson TE, Porta C, Bracarda S, et al Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-56.
7. Baselga J, Campone M, Piccart M, Burris HAIII, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366:520-9.
8. Lackner MR, Wilson TR, Settleman J. Mechanisms of acquired resistance to targeted cancer therapies. Future Oncol 2012; 8:999-1014.
9. Flaherty KT, Infante JR, Daud A, Gonzalez R., Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367:1694-703.
10. Liu P, Cheng H, Santiago S., Raeder M, Zhang F, Isabella A, et al. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med 2011; 17:1116-20.
11. Ilic N, Utermark T, Widlund H.R., Roberts TM. PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc Natl Acad Sci U S A 2011; 108:E699-U07.
12. Serra V, Eichhorn PJA, Garcia-Garcia C, Ibrahim YH, Prudkin L, Sanchez G., et al. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest 2013; 123:2551-63.
13. Edgar KA, Crocker L, Cheng E., Wagle MC, Wongchenko M, Yan Y, et al Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition. Genes Cancer 2014; 5:113-26.
14. Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelossof RA, Brook S, et al. AXL mediates resistance to PI3Kalpha inhibition by activating the EGFR/PKC/ mTOR axis in head and neck and esophageal squamous cell carcinomas. Cancer Cell 2015; 27:533-46.
15. Huw LY, O'Brien C, Pandita A, Mohan S., Spoerke JM, Lu S, et al. Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer. Oncogenesis 2013; 2:e83.
16. Costa C, Ebi H, Martini M., Beausoleil SA, Faber AC, Jakubik CT, et al Measurement of PIP3 levels reveals an unexpected role for p110beta in early adaptive responses to p110alpha-specific inhibitors in luminal breast cancer. Cancer Cell 2015; 27:97-108.
17. Juric D, Castel P, Griffith M., Griffith OL, Won HH, Ellis H, et al Convergent loss of PTEN leads to clinical resistance to a PI(3)Kalpha inhibitor. Nature 2015; 518:240-4.
18. Jia S, Liu Z, Zhang S., Liu P, Zhang L, Lee S.H., et al. Essential roles of PI(3)K-p110betaincellgrowth, metabolism and tumorigenesis. Nature 2008; 454: 776-9.
19. Guertin DA, Stevens DM, Saitoh M, Kinkel S., Crosby K, Sheen JH, et al mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 2009; 15:148-59.
20. Schwartz S, Wongvipat J, Trigwell C.B., Hancox U., Carver BS, Rodrik-Outmezguine V, et al. Feedback suppression of PI3Kalpha signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kbeta. Cancer Cell 2015; 27:109-22.
21. Folkes AJ, Ahmadi K, Alderton W.K., Alix S., Baker SJ, Box G, et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 2008; 51:5522-32.
22. O'Brien C., Wallin JJ, Sampath D, GuhaThakurta D., Savage H, Punnoose EA, et al Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 2010; 16:3670-83.
23. Ndubaku CO, Heffron TP, Staben S.T., Baumgardner M., Blaquiere N, Bradley E, et al Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1, 2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a beta-sparing phos-phoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity. J Med Chem 2013; 56:4597-610.
24. Sutherlin DP, Bao L, Berry M., Castanedo G, Chuckowree I, Dotson J., et al. Discovery of a potent, selective, and orally available class I phosphatidy-linositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J Med Chem 2011; 54: 7579-87.
25. Wallin JJ, Edgar KA, Guan J, Berry M., Prior WW, Lee L, et al. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther 2011; 10:2426-36.
26. Blake JF, Xu R, Bencsik J.R., Xiao D., Kallan NC, Schlachter S, et al. Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors. J Med Chem 2012; 55: 8110-27.
27. Pei Z, Blackwood E, Liu L., Malek S, Belvin M, Koehler M.F., et al. Discovery and biological profiling of potent and selective mTOR inhibitor GDC-0349. ACS Med Chem Lett 2013; 4:103-7.
28. Spoerke JM, O'Brien C, Huw L, Koeppen H., Fridlyand J, Brachmann RK, et al Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin Cancer Res 2012; 18:6771-83.
29. Powles TO, Escudier S, Brown B.J., Hawkins JE, Castellano RE, Ravaud DE, et al 2014 Arandomized phaseIIstudy of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT). J Clin Oncol 32:5s, 2014 (suppl; abstr 4525).
30. Nakanishi Y, Akiyama N, Tsukaguchi T., Fujii T, Sakata K, Sase H., et al. The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. Mol Cancer Ther 2014; 13:2547-58.
31. Liu J, McCleland M, Stawiski E.W., Gnad F., Mayba O, Haverty PM, et al Integratedexomeandtranscriptome sequencing reveals ZAK isoformusage in gastric cancer. Nat Commun 2014; 5:3830.
32. Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, et al. Recurrent R-spondin fusions in colon cancer. Nature 2012; 488:660-4.
33. Nakanishi Y, Akiyama N, Tsukaguchi T., Fujii T, Satoh Y, Ishii N., et al. Mechanism of oncogenic signal activation by the novel fusion kinase FGFR3-BAIAP2L1. Mol Cancer Ther 2015; 14:704-12.
34. Tanaka H, Yoshida M, Tanimura H., Fujii T, Sakata K, Tachibana Y., et al. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res 2011; 17:3272-81.
35. Frazzetto M, Suphioglu C, Zhu J., Schmidt-Kittler O, Jennings IG, Cranmer S.L., et al. Dissecting isoform selectivity of PI3K inhibitors: the role of non-conserved residues in the catalytic pocket. Biochem J 2008; 414:383-90.
36. Nylander S, Kull B, Bjorkman J.A., Ulvinge JC, Oakes N, Emanuelsson BM, et al Human target validation of phosphoinositide 3-kinase (PI3K)beta: effectsonplatelets and insulin sensitivity, using AZD6482anovel PI3Kbeta inhibitor. J Thromb Haemost 2012; 10:2127-36.
37. Weigelt B, Warne PH, Lambros M.B., Reis-Filho JS, Downward J. PI3K pathway dependencies in endometrioid endometrial cancer cell lines. Clin Cancer Res 2013; 19:3533-44.
38. Cerami E, Gao J, Dogrusoz U., Gross BE, Sumer SO, Aksoy BA, et al The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2:401-4.
39. Gao J, Aksoy BA, Dogrusoz U, Dresdner G., Gross B, Sumer SO, et al Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6: p11.
40. Pao W, Miller VA, Politi K.A., Riely GJ, Somwar R, Zakowski MF, et al Acquired resistanceoflung adenocarcinomastogefitinib orerlotinib isassociated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2:e73.
41. Wu JY, Yu CJ, Chang Y.C., Yang CH, Shih JY, Yang PC. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 2011; 17:3812-21.
42. Robinson DR, Wu YM, Vats P, Su F., Lonigro RJ, Cao X, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 2013; 45:1446-51.
43. Toy W, Shen Y, Won H., Green B, Sakr RA, Will M, et al ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 2013; 45:1439-45.
44. Burke JE, Perisic O, Masson G.R., Vadas O., Williams RL. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110alpha (PIK3CA). Proc Natl Acad Sci U S A 2012; 109:15259-64.
45. Burke JE, Williams RL Synergy in activating class I PI3Ks. Trends Biochem Sci 2015; 40:88-100.
46. Zhang X, Vadas O, Perisic O., Anderson KE, Clark J, Hawkins PT, et al Structure of lipid kinase p110beta/p85beta elucidates an unusual SH2-domain-mediated inhibitory mechanism. Mol Cell 2011; 41:567-78.
47. Pazarentzos E, Giannikopoulos P, Hrustanovic G., St John J, Olivas VR, Gubens M.A., et al. Oncogenic activation of the PI3-kinase p110beta isoform via the tumor-derived PIK3Cbeta kinase domain mutation. Oncogene 2015 May 18. [Epub ahead of print].
48. Edgar KA, Wallin JJ, Berry M, Lee L.B., Prior WW, Sampath D, et al. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors. Cancer Res 2010; 70:1164-72.
49. Hatzivassiliou G, Liu B, O'Brien C, Spoerke JM, Hoeflich K.P., Haverty PM, et al. ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol Cancer Ther 2012; 11:1143-54.